Understand the source comparison
CIRS Peptides 2026 Update: Protocol Comparison
VIP 60–70mcg twice daily (total 120–140mcg) 200mcg once daily Intranasal spray VPAC1/VPAC2 receptor activation reduces IL-6, TNF-alpha production in hypothalamus and nasal mucosa C4a begins declining within 3–4 weeks; TGF-beta-1 responds in 8–12 weeks Lower do
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- VIP
- 60–70mcg twice daily (total 120–140mcg)
- 200mcg once daily
- Intranasal spray
- VPAC1/VPAC2 receptor activation reduces IL-6, TNF-alpha production in hypothalamus and nasal mucosa
- C4a begins declining within 3–4 weeks; TGF-beta-1 responds in 8–12 weeks
- Lower dose with divided administration reduces side effects by 30% while maintaining equivalent C4a normalization rates. This is now the evidence-based standard
- BPC-157
- 500mcg daily subcutaneous
- 500mcg daily (oral or subcutaneous)
- Subcutaneous injection
- Growth hormone receptor upregulation restores intestinal tight junction proteins
- Zonulin reduction measurable at 6–8 weeks; MMP-9 normalizes at 10–14 weeks
- Subcutaneous route significantly outperforms oral due to gastric degradation. Start only after 4 weeks of VIP stabilization, not simultaneously
- Thymosin Beta-4
- 750mcg–1mg twice weekly
- 750mcg daily
- Actin polymerization and angiogenesis support tissue regeneration in chronically inflamed areas
- Exercise tolerance and cognitive improvement within 4–6 weeks of starting
- Twice-weekly dosing maintains therapeutic levels with lower injection burden. Introduce only after VIP + BPC-157 establish baseline repair, not earlier